我國從2009年開始實行基本藥物制度，有利于解決用藥貴、用藥難等現(xiàn)實問題。但是基本藥物普及性的提高更加突出了藥物不良反應（ADR）監(jiān)測的重要性，為保障用藥安全，藥品上市后的安全性再評價十分重要。為了加強國家基本藥物ADR的監(jiān)測工作，闡述我國基本藥物ADR監(jiān)測的現(xiàn)狀及存在問題，并提出完善法律體系、明晰基本藥物的遴選標準、提高各主體ADR認識的實施建議，為合理用藥、保障公眾健康提供指導。

In order to obtain drugs conveniently and cheaply, the national essential drug policy has been implemented formed in China since 2009. However, due to the improvement of national essential drug popularity, the adverse drug reaction (ADR) monitoring became more important, and the post-marketing safety re-evaluation is very important for protecting the health of patients. The aim of this article is to guide the rational use of drugs and protect human health, and the current status of ADR monitoring of national essential drugs is discussed. Some advices were provided to enhance the ADR monitoring of national essential drugs, including constituting policy system, detailing the national essential drug criteria, and encouraging the spontaneous reporting of ADRs.